Trending at Lumira Ventures

Archemix’ ARC1779 Granted Orphan Designation in EU…

admin Portfolio News

CAMBRIDGE, Mass. — Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics for rare hematological diseases, today announced that ARC1779 has received orphan drug designation from the European Commission (EC). ARC1779 also received orphan drug designation …